# Bioxyne

> Redefining Medicine


## Posts

- [Bioxyne 2025: Manufacturing psychedelics for PTSD](https://bioxyne.com/bioxyne-2025-manufacturing-psychedelics-for-ptsd/): Bioxyne CEO and Managing Director Sam Watson talked with Proactive about the company’s major developments across medical psychedelics and cannabis in 2025, highlighting growing domestic and international momentum. Watson described Bioxyne as a pharmaceutical manufacturer targeting patients with unmet clinical needs. Through its wholly owned subsidiary Breathe Life Sciences, the company produces treatments including medical cannabis, MDMA, and psilocybin for conditions such as PTSD, chronic pain, and depression. He noted the growing demand and acceptance for these treatments, especially in Australia, where Bioxyne has delivered locally manufactured MDMA batches to a Victorian government hospital. “We were the first and one […]
- [President Zelensky Signs Bill Legalizing Medical Cannabis in Ukraine](https://bioxyne.com/president-zelensky-signs-bill-legalizing-medical-cannabis-in-ukraine/): In February 2024, Ukraine took a historic step. President Volodymyr Zelensky signed into law a bill legalizing the use of medical cannabis, marking a turning point in the country’s healthcare landscape — and perhaps in its collective healing. For a nation still grappling with the deep scars of war, this reform carries a significance far beyond medicine. It’s a gesture of compassion, progress, and resilience. The new law allows cannabis-based medicines to be prescribed for conditions such as chronic pain, cancer-related symptoms, and post-traumatic stress disorder. In a country where millions live with the physical and psychological toll of conflict, […]
- [Psilocybin and depression: what this new meta-analysis tells us](https://bioxyne.com/psilocybin-depression/): In recent years, psychedelic therapy has gone from fringe curiosity to front-page science. The idea that substances like psilocybin — the psychoactive compound found in so-called “magic mushrooms” — could lift the fog of depression has sparked both fascination and controversy. Now, a new systematic review and meta-analysis published in The BMJ (Metaxa & Clarke, 2024; DOI: 10.1136/bmj-2023-078084) offers one of the clearest pictures yet of what psilocybin might actually do for people living with depression. The verdict? It works better than placebo — but the story is far from simple. What the study did Athina-Marina Metaxa and Mike Clarke […]

## Pages

- [Get in Touch](https://bioxyne.com/get-in-touch/)
- [News](https://bioxyne.com/news/): Here, we share stories about our research, innovations in biotechnology, partnerships, and the people behind our mission to support better health from within. Stay informed, stay inspired, and explore how Bioxyne continues to advance science for a healthier tomorrow.
- [The Group and Brands](https://bioxyne.com/the-group-and-brands/)
- [The Team](https://bioxyne.com/the-team/)
- [Company](https://bioxyne.com/company/): <ul class=”fadein”> <li><strong>Breathe Life Sciences (BLS)</strong> produce e distribuisce prodotti per la salute e il benessere, tra cui integratori, estratti di cannabis non controllata (CBD), probiotici (<em>PCC</em>), funghi medicinali, cannabis terapeutica, MDMA e psilocibina, operando in Australia, Regno Unito ed Europa.</li> <li><strong>Dr Watson®</strong> propone prodotti per la salute e farmaci da prescrizione fabbricati da BLS e terzi, venduti in Australia, Regno Unito, Germania e Giappone. La gamma comprende capsule, compresse, soluzioni orali e preparati erboristici con probiotici <em>(Lactobacillus Fermentum PCC®)</em>, funghi, SL-NAD+ e cannabis terapeutica.</li> <li><strong>Ricerca e sviluppo</strong> di nuove formulazioni e processi per ampliare le capacità produttive e l’efficienza, […]
- [Homepage](https://bioxyne.com/)


[comment]: # (Generated by Hostinger Tools Plugin)